GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taisho Pharmaceutical Holdings Co Ltd (TSE:4581) » Definitions » YoY EBITDA Growth

Taisho Pharmaceutical Holdings Co (TSE:4581) YoY EBITDA Growth : -64.13% (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Taisho Pharmaceutical Holdings Co YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Taisho Pharmaceutical Holdings Co's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was -64.13%.

Taisho Pharmaceutical Holdings Co's EBITDA per Share for the three months ended in Dec. 2023 was 円55.41.


Taisho Pharmaceutical Holdings Co YoY EBITDA Growth Historical Data

The historical data trend for Taisho Pharmaceutical Holdings Co's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taisho Pharmaceutical Holdings Co YoY EBITDA Growth Chart

Taisho Pharmaceutical Holdings Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.56 -38.10 -3.72 -3.14 20.86

Taisho Pharmaceutical Holdings Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.34 -106.39 -22.68 -26.34 -64.13

Taisho Pharmaceutical Holdings Co YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Taisho Pharmaceutical Holdings Co's YoY EBITDA Growth for the fiscal year that ended in Mar. 2023 is calculated as:

YoY EBITDA Growth (A: Mar. 2023 )
=(EBITDA per Share (A: Mar. 2023 )-EBITDA per Share (A: Mar. 2022 ))/ | EBITDA per Share (A: Mar. 2022 ) |
=(661.692-547.493)/ | 547.493 |
=20.86 %

Taisho Pharmaceutical Holdings Co's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (Q: Dec. 2023 )
=(EBITDA per Share (Q: Dec. 2023 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(55.405-154.456)/ | 154.456 |
=-64.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Taisho Pharmaceutical Holdings Co YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Taisho Pharmaceutical Holdings Co's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Taisho Pharmaceutical Holdings Co (TSE:4581) Business Description

Traded in Other Exchanges
Address
3-24-1 Takada, Toshima-ku, Tokyo, JPN, 170-8655
Taisho Pharmaceutical Holding Co Ltd is a specialty and generic drug manufacturing company. The company maintains two operational segments, Self-Medication and Prescription Pharmaceuticals. The vast majority of Taisho's revenue is derived from its Self-Medication segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The vast majority of sales are generated by sales to external customers in Japan.

Taisho Pharmaceutical Holdings Co (TSE:4581) Headlines

No Headlines